• Integrated transcriptomic and proteomic analysis identified a five-biomarker panel with 92% sensitivity and 88% specificity for early HCC detection.
• A prognostic signature based on the biomarkers effectively stratifies HCC patients into distinct risk groups with significant survival differences.
• Novel candidate biomarkers were validated in independent cohorts, demonstrating reproducibility and clinical utility.
• The multi-omics approach offers a comprehensive framework for personalized HCC diagnosis and treatment.
Download Full PDF: A Comprehensive Analysis of Hepatocellular Carcinoma Biomarkers: Integrating Transcriptomic and Proteomic Approaches for Early Diagnosis and Prognosis | SinoBioData | SinoBioData